Table of Contents
Introduction
Diazepam is a long-acting benzodiazepine widely used for its anxiolytic, sedative–hypnotic, anticonvulsant, muscle relaxant, and amnestic properties. It acts on the central nervous system by enhancing inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA). Diazepam is a high-yield drug in pharmacology, psychiatry, neurology, anesthesia, and emergency medicine examinations due to its rapid onset, multiple indications, and characteristic mechanism of action.


Mechanism of Action (Step-wise)
Diazepam enhances inhibitory neurotransmission by modulating the GABA-A receptor–chloride channel complex.
Step-wise mechanism:
- GABA-A Receptor Complex
The GABA-A receptor is a ligand-gated chloride ion channel located on postsynaptic neuronal membranes. - Binding Site of Diazepam
Diazepam binds to a specific allosteric site on the GABA-A receptor, distinct from the GABA binding site. - Allosteric Modulation
Binding of diazepam increases the affinity of the GABA-A receptor for endogenous GABA. - Increased Frequency of Chloride Channel Opening
In the presence of GABA, diazepam increases the frequency (not duration) of chloride channel opening. - Chloride Ion Influx
Increased chloride influx leads to hyperpolarization of the postsynaptic neuron. - Reduced Neuronal Excitability
Hyperpolarization makes neurons less likely to fire action potentials. - Central Nervous System Depression
The net result is anxiolytic, sedative, anticonvulsant, and muscle relaxant effects.
Pharmacokinetics
- Absorption: Rapid and complete oral absorption
- Distribution: Highly lipophilic; widely distributed; crosses blood–brain barrier and placenta
- Protein binding: High
- Metabolism: Hepatic metabolism via CYP2C19 and CYP3A4
- Active metabolites: Desmethyldiazepam, oxazepam, temazepam
- Elimination: Renal excretion of metabolites
- Half-life: Long (20–50 hours; metabolites longer)
Because of active metabolites, diazepam has a prolonged duration of action.
Clinical Uses
Diazepam is used in multiple neurologic and psychiatric conditions:
- Anxiety disorders
- Acute alcohol withdrawal
- Status epilepticus (IV)
- Muscle spasm and spasticity
- Premedication before procedures
- Sedation and anxiolysis
- Tetanus (adjunct therapy)
Adverse Effects
Adverse effects are related to CNS depression:
- Central nervous system:
- Sedation
- Drowsiness
- Ataxia
- Confusion (especially in elderly)
- Respiratory depression (high doses or IV use)
- Dependence and tolerance with long-term use
- Anterograde amnesia
Abrupt discontinuation after prolonged use can precipitate withdrawal symptoms and seizures.
Comparative Analysis (must include a table + explanation)
Comparison of GABAergic Sedative-Hypnotics
| Feature | Diazepam | Barbiturates | Z-drugs |
|---|---|---|---|
| Receptor | GABA-A | GABA-A | GABA-A |
| Channel effect | ↑ Frequency | ↑ Duration | ↑ Frequency |
| Therapeutic index | High | Low | High |
| Respiratory depression | Rare alone | Common | Rare |
| Dependence risk | Moderate | High | Low |
Explanation:
Diazepam is safer than barbiturates because it enhances GABA action without directly opening chloride channels. Unlike Z-drugs, diazepam has broad anticonvulsant and muscle relaxant properties.
MCQs (10–15)
- Diazepam acts by binding to which receptor?
a) GABA-B
b) NMDA
c) GABA-A
d) Dopamine D₂
Answer: c) GABA-A
- Diazepam increases which property of the chloride channel?
a) Conductance
b) Duration of opening
c) Frequency of opening
d) Number of channels
Answer: c) Frequency of opening
- Diazepam requires the presence of which neurotransmitter to act?
a) Dopamine
b) Serotonin
c) GABA
d) Acetylcholine
Answer: c) GABA
- Diazepam produces CNS depression by causing:
a) Neuronal depolarization
b) Sodium influx
c) Neuronal hyperpolarization
d) Calcium channel opening
Answer: c) Neuronal hyperpolarization
- Diazepam is most useful in:
a) Chronic psychosis
b) Status epilepticus
c) Parkinson disease
d) Myasthenia gravis
Answer: b) Status epilepticus
- Diazepam is metabolized in the liver to:
a) Inactive metabolites only
b) Active metabolites
c) Toxic metabolites
d) Water-soluble metabolites only
Answer: b) Active metabolites
- A major advantage of diazepam over barbiturates is:
a) Faster onset
b) Lower efficacy
c) Higher safety margin
d) No sedation
Answer: c) Higher safety margin
- Long-term use of diazepam may cause:
a) Agranulocytosis
b) Dependence
c) Nephrotoxicity
d) Ototoxicity
Answer: b) Dependence
- Diazepam is contraindicated in:
a) Anxiety
b) Status epilepticus
c) Severe respiratory depression
d) Muscle spasm
Answer: c) Severe respiratory depression
- Diazepam differs from barbiturates by:
a) Acting without GABA
b) Directly opening chloride channels
c) Increasing frequency, not duration, of channel opening
d) Blocking sodium channels
Answer: c) Increasing frequency, not duration, of channel opening
FAQs (minimum 5)
- What is the primary mechanism of diazepam?
Allosteric enhancement of GABA-A receptor–mediated chloride influx. - Why is diazepam safer than barbiturates?
It does not directly open chloride channels and requires GABA to act. - Does diazepam cause muscle relaxation?
Yes, by suppressing polysynaptic spinal reflexes. - Why does diazepam have a long duration of action?
Due to formation of active metabolites. - Can diazepam cause dependence?
Yes, especially with long-term or high-dose use. - Is diazepam useful in seizures?
Yes, particularly in acute seizure management.
References
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
https://accessmedicine.mhmedical.com - Katzung BG. Basic and Clinical Pharmacology
https://accessmedicine.mhmedical.com - Tripathi KD. Essentials of Medical Pharmacology
https://www.jaypeebrothers.com - Harrison’s Principles of Internal Medicine
https://accessmedicine.mhmedical.com

I am pursuing MBA in pharmaceutical management from NIPER Hyderabad with a strong academic record and proven success in national-level pharmacy entrance exams. I secured AIR 61 in NIPER 2024 (MS/M.Pharm) and AIR 27 in NIPER MBA, along with AIR 147 in GPAT 2024 and AIR 907 in GPAT 2023. I also achieved AIR 6 in AIIMS CRE-2025 for Drug Store Keeper and was selected as a Pharmacist (AIR 61) for ESIC. Additionally, I was the Runner-Up in Round 2 of the EY Case Study Competition.
At PharmacyFreak.com, I aim to guide future pharmacists through expert content, exam strategies, and insightful resources based on real experience and academic excellence.
Mail- harsh@pharmacyfreak.com
